In every moment, we have two options either to do what is needed or to run away from it. The right thing means nothing but to do what is necessary and feels right to us, by keeping consequences in mind. If you do the right things just because someone is going to reward you, it may make doing the right thing a selfish thing. No matter what situation you are in, you should always do what is right. Doing the right thing only for gaining attention and publicity is unethical. Irrespective of results or benefits, believe in the process, and do the right thing, give justice. Doing the right is itself a reward. - Shubham Shukla

1. AMERICAN MEDICAL ASSOCIATION (AMA)
<https://m.facebook.com/AmericanMedicalAssociation/photos/a.10151410277225109/10163952007265109/?type=3&p=7>
Loretta Lynn NY
Unfortunately most people still do not understanding these simple facts.
(Mainly because the media propaganda is not reporting all the true facts about it.)
#1 - There is “No” Vaccine to give you immunization against the SARS2 Coronavirus.
#2 - Covid-19 is “Not” the virus.
It is only the name given to the Respiratory Symptoms of the SARS2 Coronavirus.
#3 - You can “Not” have Immunization to a Respiratory Symptom if you do not have immunity
against contracting the actual disease (virus) that causes it.
#4 - The reason it is being called a “Covid-19 Vaccine” instead of what is really is, a Therapeutic
Drug, is because ALL manufacturers of any drug that they refer to as a “Vaccine” gives these
companies complete immunity against ANY Liability under the “1986 Prep Act”.
So therefore, you can not sue Pfizer or Moderna or any other company that uses the word vaccine
for their drug if you experience any injury and or death from taking one of their so called
vaccines.
#5 - The Experimental Drug (Not FDA Approved) that is being referred to as the COVID-19
Vaccine is “NOT” a vaccine that gives immunization to the SARS2 Coronavirus.
It is “ONLY” a possible “Therapeutic Drug” that MIGHT help reduce the respiratory symptoms,
called Covid-19.
But the list of FDA Adverse Side Effects out weight the possible benefits and can also be
permanent side effects for the rest of your life.
It will take years for the conclusion of the results of this “Experimental Drug Trial” with using all
the data from all the people whom have volunteered to take part in this experiment.
#6 - The Experimental Drug Trial is considered “Voluntary” and may “not” be covered by your
Medical Insurance if you need medical help for any of it’s adverse side effects.
(Check your medical insurance first before you volunteer to take part in any Experimental Drug
Trial.)
#7 - If you were to die from having a severe adverse side effect by “Volunteering” to participate
in an “Experimental Drug Trial” and have a Life Insurance Plan it may cancel it out because it
might not cover deaths from an Experimental Drug Trial.
(Check your Life Insurance Policy before volunteering in any Experimental Drug Trial.)

2. #8 - There are plenty of medical therapeutic drugs that physicians are successfully using but do
not have the dangerous adverse side effects that the FDA has listed in their documents for this
Experimental Drug being called the “Covid-19 Vaccine”.
But unfortunately these Physicians are being censored by Big Tech, Big Pharm, the CDC and so
on, because the FDA can only allow an unapproved drug to be used as an EUA if they don't
allow any other drug to be considered.
Thus, why all other FDA approved therapeutic drugs are not being considered for the treatment
of the SARS2 Coronavirus Respiratory Symptoms.
______________________________________________________
HYDROXYCHLOROQUINE
The American Medical Association did not change its stance from opposing to supporting the use
of hydroxychloroquine as a treatment for COVID-19. The association supports the ability of
health practitioners to prescribe drugs based on their professional judgement, but insists
that practitioners rely on evidence-based medicine. So far, there is no scientific support for the
claim that hydroxychloroquine can prevent COVID-19 deaths.
Source:
The American Medical Association does not reject nor support hydroxychloroquine as a treatment for
COVID-19, nor did it change its position on the use matter
By Brian C. Joondeph, American Thinker, 18 December 2020
<https://healthfeedback.org/claimreview/the-american-medical-association-does-not-reject-nor-support-hydroxychloroquine-as-a-treatment-for-covid-19-nor-did-it-change-its-
position-on-the-use-matter/>
IVERMECTIN
The Food and Drug Administration (FDA) echoed the CDC's warning against the use of
ivermectin for prevention or treatment of COVID-19. That is because ivermectin is not
approved or authorized by the FDA for COVID-19. Additionally, the National Institutes of
Health's (NIH) COVID-19 Treatment Guidelines Panel determined that there is insufficient
evidence and data to recommend ivermectin for treatment of COVID-19. This
recommendation is consistent with the Infectious Disease Society of America's Guidelines on the
Treatment and Management of Patients with COVID-19, which speaks against the use of
ivermectin in hospitalized patients and ambulatory persons with COVID-19, outside of the
context of a clinical trial. There is also no evidence to suggest that ivermectin can be used to
successfully prevent COVID-19 infection.
“Clinical trials and observational studies to evaluate the use of ivermectin to prevent and treat
COVID-19 in humans have yielded insufficient evidence for the NIH COVID-19 Treatment
Guidelines Panel to recommend its use,” the CDC health alert explains. “Data from adequately
sized, well-designed and well-conducted clinical trials are needed to provide more specific,
evidence-based guidance on the role of ivermectin in the treatment of COVID-19.”
A recent study cited by the CDC found that ivermectin dispensing from outpatient retail
pharmacies in the U.S. increased from an average of 3,600 prescriptions per week at the pre-
pandemic baseline to a peak of 39,000 prescriptions in the week ending Jan. 8, 2021.

3. Then, since early July, outpatient ivermectin dispensing was on the rise again, rapidly increasing
to more than 88,000 prescriptions in the week ending Aug. 13. According to the CDC, this
represents a 24-fold increase. This growing interest in ivermectin to treat humans with COVID-
19 has led to an increase in calls to poison control reporting overdoses and adverse effects.
[Emphasis Supplied]
Source:
Why ivermectin should not be used to prevent or treat COVID-19
By Sara Berg, American Medical Association, August 27, 2021
<https://www.ama-assn.org/delivering-care/public-health/why-ivermectin-should-not-be-used-prevent-or-treat-covid-19>
______________________________________________________
COVID-19 THERAPEUTICS: WHAT THE EVIDENCE SHOWS
By Tanya Albert Henry, American Medical Association, March 29, 2021 [Extract]
<https://www.ama-assn.org/delivering-care/public-health/covid-19-therapeutics-what-evidence-shows>
Effective vaccines mean that the COVID-19 pandemic may be more controlled in the coming
months, but the SARS-CoV-2 virus will likely remain a part of our everyday lives. That makes it
important for physicians to have therapeutics in their toolbox to treat patients at all stages of
disease progression—today, as well as in the future.
Treatments for mild COVID-19
Since the earliest days of the pandemic, a few options for treating patients with mild to moderate
COVID-19 have been discovered and they are aimed at keeping high-risk patients out of the
hospital and preventing mortality, said John Farley, MD, director of the FDA’s infectious
diseases office in the FDA Center for Drug Evaluation and Research (CDER). Monoclonal
antibodies (mAbs) are designed to block SARS-CoV-2 viral attachment and entry into human
cells, neutralizing the virus. At this article's deadline, there were three emergency use authorized
products:
Bamlanivimab
Bamlanivimab and etesevimab administered together
REGN-COV: casirivimab and imdevimab administered together.
The mAbs have been authorized to use for mild to moderate COVID-19 and can be used in adults
and children 12 or older and weighing at least 40 kilograms who are at high risk of developing
severe COVID-19 or progressing to hospitalization. These treatments are not authorized for
patients who are already hospitalized for COVID-19 or those who require oxygen therapy. At
least two trials have suggested using the treatment on patients already on ventilators may do more
harm than good, Dr. Farley said.
In a phase 3 trial for patients receiving the bamlanivimab and etesevimab versus placebo, there
was a 70% reduction in patients who required hospitalization or died after 29 days, he said. There
were 10 deaths for patients who received a placebo and no deaths among those who received the
treatment.
Some challenges have emerged for treating patients with these mAB infusions and the uptake of
their use has been limited, including the need to administer the mABs via infusion and short
window of time to administer them—treatment must be given within 10 days of symptom onset.
Additionally, research has indicated that circulating SARS-CoV-2 viral variants may be
associated with resistance to mABs.

4. Information on resistance can be found in the FDA fact sheets and from state and local public
health authorities.
Treatments for sicker patients
Remdesivir. This intravenous drug can be used in hospitalized adult patients and children 12
years or older who weigh at least 40 kilograms.
Immonomodulators. Several immunomodulator therapies have also been used with some success,
said Sally Seymour, MD, the deputy director for safety in the pulmonary, allergy and
rheumatology products division at CDER. They are dexamethasone, baricitnib and tocilizumab.
Dexamethasone can be used for hospitalized patients on oxygen or a ventilator after a study
published in The New England Journal of Medicine found that, overall, the treatment resulted in
a 3% reduction in mortality. For those on a ventilator, there was 12% reduction in mortality, Dr.
Seymour said.
Baricitnib was authorized for emergency use in November for COVID-19 patients in
combination with remdesivir for patients 2 and older on supplemental oxygen, a mechanical
ventilator or extracorporeal membrane oxygenation machine. A National Institutes of Health
(NIH)-sponsored study showed it reduced recovery time by one day, to seven days, and that it
reduced the odds of a patient dying or going on a mechanical ventilator.
Tocilizumab trials have had mixed results, but recently released data in a nonpeer-reviewed
preprint article shows absolute mortality reduced by 4%. NIH issued a statement for use in
certain patients.
Early in the pandemic, researchers turned to existing drugs to determine whether they could
effectively treat COVID-19. While research continues on that front, scientists are also looking at
new or repurposed, never approved antivirals that can treat COVID-19 early in the disease, Dr.
Woodcock said. Dr. Farley said it’s important to look for treatments that have clinical benefit for
the patient. For example, there are companies working medication that would improve symptoms
faster. The idea is to obtain drugs to help alleviate COVID-19 symptoms in the way that
oseltamivir (marketed as Tamiflu) can help treat patients with influenza. The priority, he said, is
“to keep our highest-risk patients out of the hospital right now, and hopefully we are getting
those high-risk patients vaccinated as quickly as possible.”
Journal of Applied Biological Sciences
Dr. Mehmet Karataş
Responsibility Of Physicians